Compare DSX & TLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DSX | TLSI |
|---|---|---|
| Founded | 1999 | 2010 |
| Country | Greece | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 273.7M | 270.2M |
| IPO Year | 2005 | 2020 |
| Metric | DSX | TLSI |
|---|---|---|
| Price | $2.73 | $4.93 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $7.00 |
| AVG Volume (30 Days) | ★ 911.8K | 173.0K |
| Earning Date | 05-28-2026 | 05-12-2026 |
| Dividend Yield | ★ 1.62% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $45,151,000.00 |
| Revenue This Year | $14.28 | $35.45 |
| Revenue Next Year | $4.87 | $37.58 |
| P/E Ratio | $16.02 | ★ N/A |
| Revenue Growth | N/A | ★ 53.41 |
| 52 Week Low | $1.57 | $2.20 |
| 52 Week High | $2.92 | $7.95 |
| Indicator | DSX | TLSI |
|---|---|---|
| Relative Strength Index (RSI) | 64.34 | 50.03 |
| Support Level | $2.27 | $4.21 |
| Resistance Level | $2.90 | $5.58 |
| Average True Range (ATR) | 0.09 | 0.30 |
| MACD | 0.01 | -0.09 |
| Stochastic Oscillator | 86.73 | 21.89 |
Diana Shipping Inc provides shipping transportation services. The company, through its subsidiaries, operates a fleet of vessels consisting of dry bulk carriers such as Panamax, Kamsarmax, Post-Panamax, Capesize, and Newcastlemax vessels. Using this fleet, the firm provides transportation services for various goods, including coal, iron ore, and grains. It also transports minor bulks, including steel products, cement, and fertilizers, through its dry bulk carrier vessels. The operation of the vessels is the main source of revenue generation; the services provided by the vessels are similar, and all operate under the same economic environment.
TriSalus Life Sciences Inc is an oncology-focused medical technology business integrating its delivery technology with standard-of-care therapies and its investigational immunotherapeutic, nelitolimod, a class C Toll-like receptor 9 (TRL9) agonist, for patients with solid tumors. The company developed Pressure-Enabled Drug Delivery (PEDD) to overcome high intratumoral pressure and off-target delivery. Its 510(k) cleared device, the TriNav Infusion System using PEDD technology, is used for interventional radiology procedures including transarterial radioembolization (TARE) and transarterial chemoembolization (TACE) in patients with primary liver cancer or liver metastases. It has one reportable segment and generates revenue from sales of PEDD infusion systems, principally related to TriNav.